Bio-Rad to Buy Germany's AbD Serotec for $70 Million

On Monday, Bio-Rad Laboratories (NYSE: BIO  ) (NYSE: BIO-B  ) announced a definitive agreement to buy the AbD Serotec division of Germany's MorphoSys AG for $69.8 million  cash. The transaction is slated to close in January.

In a statement, Bio-Rad's Life Science Group President Brad Crutchfield observed that Serotec brings with it "access to a comprehensive catalog of antibodies allowing us to better serve our customers by offering total assay solutions that can be validated on our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting. In addition, we will be able to exploit a powerful in vitro technology to accelerate future antibody generation."

According to S&P Capital IQ, Serotec is profitable, earning $1.2 million in 2011 on $25.1 million in revenues.

Bio-Rad shares declined 0.3% to close the day at $103.98.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2158505, ~/Articles/ArticleHandler.aspx, 11/26/2014 10:17:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement